1. Home
  2. CGC vs LRMR Comparison

CGC vs LRMR Comparison

Compare CGC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canopy Growth Corporation

CGC

Canopy Growth Corporation

HOLD

Current Price

$0.85

Market Cap

389.2M

Sector

Health Care

ML Signal

HOLD

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

SELL

Current Price

$2.70

Market Cap

455.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CGC
LRMR
Founded
N/A
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
389.2M
455.8M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
CGC
LRMR
Price
$0.85
$2.70
Analyst Decision
Buy
Strong Buy
Analyst Count
3
11
Target Price
$1.95
★ $14.40
AVG Volume (30 Days)
★ 1.9M
1.4M
Earning Date
11-06-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 84.17
N/A
EPS
★ N/A
N/A
Revenue
★ $12,759,000.00
N/A
Revenue This Year
$21.39
N/A
Revenue Next Year
$8.33
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$2.72
52 Week High
$2.38
$6.42

Technical Indicators

Market Signals
Indicator
CGC
LRMR
Relative Strength Index (RSI) 28.16 24.50
Support Level N/A N/A
Resistance Level $0.98 $3.76
Average True Range (ATR) 0.03 0.19
MACD -0.01 -0.08
Stochastic Oscillator 14.60 5.24

Price Performance

Historical Comparison
CGC
LRMR

About CGC Canopy Growth Corporation

Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Share on Social Networks: